India, Aug. 11 -- Clearmind Medicine Inc. (CMND), a clinical-stage biotechnology company, on Tuesday reported positive permeation results from its ongoing intranasal MEAI development program, with 97.35% cumulative permeation at 180 minutes, compared with 98.34% for a conventional MEAI formulation.
The study evaluated whether the company's proprietary mucoadhesive intranasal formulation affects the release and membrane transport of MEAI (5-Methoxy-2-aminoindane) compared with a conventional MEAI solution.
Using Franz diffusion cells, a cellulose dialysis membrane and simulated nasal electrolyte solution, the study compared equivalent doses of the two formulations. Both showed rapid and extensive permeation, although intranasal MEAI had a ...